 |
30 Diseases |  |
0 Trials |
|
0 Trials |  |
39 News |  |
- || BMS-936559 / BMS
Biomarker, Clinical, P1 data, Journal, Checkpoint inhibition, PD(L)-1 Biomarker, IO Biomarker: Immune Checkpoint Inhibition in Sepsis: A Phase 1b Randomized, Placebo-Controlled, Single Ascending Dose Study of Antiprogrammed Cell Death-Ligand 1 (BMS-936559). (Pubmed Central) - Feb 20, 2020
In this first clinical evaluation of programmed cell death protein-1/programmed cell death-ligand 1 pathway inhibition in sepsis, BMS-936559 was well tolerated, with no evidence of drug-induced hypercytokinemia or cytokine storm, and at higher doses, some indication of restored immune status over 28 days. Further randomized trials on programmed cell death protein-1/programmed cell death-ligand 1 pathway inhibition are needed to evaluate its clinical safety and efficacy in patients with sepsis.
- | Opdivo (nivolumab) / Ono Pharma, BMS
Clinical, Journal, PD(L)-1 Biomarker, IO Biomarker: Blockade of the PD-1 axis alone is not sufficient to activate HIV-1 virion production from CD4+ T cells of individuals on suppressive ART. (Pubmed Central) - Oct 24, 2019
Cell surface expression of PD-1 and PD-L1 were not associated with changes in virus production. Ex vivo blockade of the PD-1 axis alone has limited effects on HIV-1 latency.
- | Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Journal: Immunotherapy in Lung Cancer: A New Age in Cancer Treatment. (Pubmed Central) - Jun 4, 2019
It also analyzes the different studies that have been developed for NSCLC with these medications, the evidence obtained, and the possible role in the management of patients. Immunotherapy has definitely changed the paradigm on NSCLC treatment, and the future is promising for the benefit of patients.
- | Opdivo (nivolumab) / Ono Pharma, BMS, BMS-936559 / BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Journal: Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early Time-Point FDG-PET/CT Imaging in Patients with Advanced Melanoma. (Pubmed Central) - Oct 5, 2017
Combining functional and anatomic imaging parameters from FDG-PET/CT scans performed early in ICI appears predictive for eventual response in patients with advanced melanoma. These findings require validation in larger cohorts.
- BMS-936559 / BMS
Trial termination, PD(L)-1 Biomarker, IO biomarker: Safety, Pharmacokinetics and Pharmacodynamics of BMS-936559 in Severe Sepsis (clinicaltrials.gov) - Sep 15, 2017
P1b/2a, N=35, Terminated, Sponsor: Bristol-Myers Squibb
These findings require validation in larger cohorts. Active, not recruiting --> Terminated; Business Objectives Have Changed
- | BMS-936559 / BMS
Enrollment closed, Enrollment change, Trial primary completion date, PD(L)-1 Biomarker, IO biomarker: Safety, Pharmacokinetics and Pharmacodynamics of BMS-936559 in Severe Sepsis (clinicaltrials.gov) - Aug 2, 2017
P1b/2a, N=35, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Terminated; Business Objectives Have Changed Recruiting --> Active, not recruiting | N=225 --> 35 | Trial primary completion date: Jun 2018 --> Mar 2017
- || BMS-936559 / BMS
Trial primary completion date, PD(L)-1 Biomarker, IO biomarker: Safety, Pharmacokinetics and Pharmacodynamics of BMS-936559 in Severe Sepsis (clinicaltrials.gov) - Jul 19, 2016
P1b/2a, N=225, Recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting | N=225 --> 35 | Trial primary completion date: Jun 2018 --> Mar 2017 Trial primary completion date: Sep 2018 --> Jun 2018
- | BMS-936559 / BMS
Phase classification, PD(L)-1 Biomarker, IO biomarker: Safety, Pharmacokinetics and Pharmacodynamics of BMS-936559 in Severe Sepsis (clinicaltrials.gov) - Jun 13, 2016
P1b/2a, N=225, Recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Sep 2018 --> Jun 2018 Phase classification: P1/2 --> P1b/2a
- || BMS-936559 / BMS
Trial primary completion date, PD(L)-1 Biomarker, IO biomarker: Safety, Pharmacokinetics and Pharmacodynamics of BMS-936559 in Severe Sepsis (clinicaltrials.gov) - May 27, 2016
P1/2, N=225, Recruiting, Sponsor: Bristol-Myers Squibb
Phase classification: P1/2 --> P1b/2a Trial primary completion date: Jan 2018 --> Sep 2018
- |||| BMS-936559 / BMS
Enrollment open, PD(L)-1 Biomarker, IO biomarker: Safety, Pharmacokinetics and Pharmacodynamics of BMS-936559 in Severe Sepsis (clinicaltrials.gov) - Jan 20, 2016
P1/2, N=225, Recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Jan 2018 --> Sep 2018 Not yet recruiting --> Recruiting
- BMS-936559 / BMS
Trial completion, Enrollment change, Trial primary completion date, PD(L)-1 Biomarker, IO biomarker: Safety and Immune Response of BMS-936559 in HIV-Infected People Taking Combination Antiretroviral Therapy (clinicaltrials.gov) - Dec 29, 2015
P1, N=8, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting --> Recruiting Suspended --> Completed | N=56 --> 8 | Trial primary completion date: May 2016 --> Nov 2015
- ||||| BMS-936559 / BMS
New P1/2 trial, PD(L)-1 Biomarker, IO biomarker: Safety, Pharmacokinetics and Pharmacodynamics of BMS-936559 in Severe Sepsis (clinicaltrials.gov) - Oct 22, 2015
P1/2, N=225, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- ||| BMS-936559 / BMS
Trial completion, PD(L)-1 Biomarker, Metastases: Multiple Ascending Dose (MDX1105-01) (clinicaltrials.gov) - Sep 8, 2015
P1, N=281, Completed, Sponsor: Bristol-Myers Squibb
Suspended --> Completed | N=56 --> 8 | Trial primary completion date: May 2016 --> Nov 2015 Active, not recruiting --> Completed
- || BMS-936559 / BMS
Trial primary completion date, PD(L)-1 Biomarker, Metastases: Multiple Ascending Dose (MDX1105-01) (clinicaltrials.gov) - Apr 28, 2015
P1, N=286, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed Trial primary completion date: Jan 2015 --> Jul 2015
- BMS-936559 / BMS
Trial suspension, PD(L)-1 Biomarker, IO biomarker: Safety and Immune Response of BMS-936559 in HIV-Infected People Taking Combination Antiretroviral Therapy (clinicaltrials.gov) - Feb 23, 2015
P1, N=56, Suspended, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Jan 2015 --> Jul 2015 Recruiting --> Suspended
- BMS-936559 / BMS
Trial primary completion date, PD(L)-1 Biomarker, IO biomarker: Safety and Immune Response of BMS-936559 in HIV-Infected People Taking Combination Antiretroviral Therapy (clinicaltrials.gov) - Feb 5, 2015
P1, N=56, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Suspended Trial primary completion date: Jun 2015 --> May 2016
- BMS-936559 / BMS
Trial primary completion date, PD(L)-1 Biomarker, IO biomarker: Safety and Immune Response of BMS-936559 in HIV-Infected People Taking Combination Antiretroviral Therapy (clinicaltrials.gov) - Nov 12, 2014
P1, N=56, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Jun 2015 --> May 2016 Trial primary completion date: Apr 2016 --> Jun 2015
- BMS-936559 / BMS
Enrollment open, PD(L)-1 Biomarker, IO biomarker: Safety and Immune Response of BMS-936559 in HIV-Infected People Taking Combination Antiretroviral Therapy (clinicaltrials.gov) - Sep 4, 2014
P1, N=56, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Apr 2016 --> Jun 2015 Not yet recruiting --> Recruiting
- || BMS-936559 / BMS
Trial primary completion date, PD(L)-1 Biomarker, Metastases: Multiple Ascending Dose (MDX1105-01) (clinicaltrials.gov) - May 6, 2014
P1, N=286, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2013 --> Jan 2015
- | BMS-936559 / BMS
Trial completion date, PD(L)-1 Biomarker, Metastases: Multiple Ascending Dose (MDX1105-01) (clinicaltrials.gov) - May 6, 2014
P1, N=286, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Dec 2013 --> Jan 2015 Trial completion date: Dec 2013 --> Jan 2015
- || BMS-936559 / BMS
Trial initiation date, PD(L)-1 Biomarker, Metastases: Multiple Ascending Dose (MDX1105-01) (clinicaltrials.gov) - May 6, 2014
P1, N=286, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Trial completion date: Dec 2013 --> Jan 2015 Initiation date: Jan 1975 --> Apr 2009
- BMS-936559 / BMS
New P1 trial, PD(L)-1 Biomarker, IO biomarker: Safety and Immune Response of BMS-936559 in HIV-Infected People Taking Combination Antiretroviral Therapy (clinicaltrials.gov) - Jan 5, 2014
P1, N=48, Not yet recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- || BMS-936559 / BMS
Enrollment closed, PD(L)-1 Biomarker, Metastases: Multiple Ascending Dose (MDX1105-01) (clinicaltrials.gov) - Mar 13, 2013
P1, N=286, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Initiation date: Jan 1975 --> Apr 2009 Recruiting --> Active, not recruiting
- BMS-936559 / BMS
Trial withdrawal: Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic Malignancy (clinicaltrials.gov) - Feb 21, 2012
P1, N=0, Withdrawn, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting Not yet recruiting --> Withdrawn
- BMS-936559 / BMS
Enrollment change: Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic Malignancy (clinicaltrials.gov) - Feb 21, 2012
P1, N=0, Withdrawn, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Withdrawn N=110 --> 0
- BMS-936559 / BMS
Biomarker, Trial withdrawal, PD(L)-1 Biomarker, IO biomarker, Metastases: Phase 1 Biomarker Study of Anti-PDL-1 in Advanced Melanoma (clinicaltrials.gov) - Dec 11, 2011
P1, N=0, Withdrawn, Sponsor: Bristol-Myers Squibb
N=110 --> 0 Not yet recruiting --> Withdrawn
- BMS-936559 / BMS
Biomarker, Enrollment change, PD(L)-1 Biomarker, IO biomarker, Metastases: Phase 1 Biomarker Study of Anti-PDL-1 in Advanced Melanoma (clinicaltrials.gov) - Dec 11, 2011
P1, N=0, Withdrawn, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Withdrawn N=80 --> 0
- BMS-936559 / BMS
Biomarker, New P1 trial, PD(L)-1 Biomarker, IO biomarker, Metastases: Phase 1 Biomarker Study of Anti-PDL-1 in Advanced Melanoma (clinicaltrials.gov) - Oct 17, 2011
P1, N=0, Withdrawn, Sponsor: Bristol-Myers Squibb
- BMS-936559 / BMS
New P1 trial: Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic Malignancy (clinicaltrials.gov) - Oct 3, 2011
P1, N=0, Withdrawn, Sponsor: Bristol-Myers Squibb